



CENTER FOR NANOTECHNOLOGY IN SOCIETY  
at Arizona State University



and

THE biodesign INSTITUTE  
ARIZONA STATE UNIVERSITY

# Nanomedicine in the NIH Roadmap: Priorities, Vision, & Implications

## Jeffery Schloss

**When:** May 3, 2006, 11 a.m.-12:30 p.m.  
**Where:** Biodesign A, Room 10/14  
**Audience:** CNS-ASU Partners

**Dr. Jeffery Schloss** is the Co-Chair of the Nanomedicine Roadmap Initiative, NIH and a program director in the Division of Extramural Research at the National Human Genome Research Institute, with responsibility for DNA sequencing technology development.

In 2002, the NIH and its leadership engaged in a process dubbed the “NIH Roadmap,” designed to ask the kind of probing questions that a complex research organization should periodically pose. The overall goal of the roadmap was to define a compelling, limited set of priorities that can be acted on and are essential to accelerate progress across the spectrum of the institute missions. For example, what if doctors could search out and destroy the very first cancer cells that would otherwise have caused a tumor to develop in the body? What if pumps the size of molecules could be implanted to deliver life-saving medicines precisely when and where they are needed? Such scenarios may sound unbelievable, but they are the long-term goals of the NIH Roadmap’s Nanomedicine initiative that they anticipate will yield medical benefits as early as 2012.

Partially funded by a grant from the National Science Foundation.

To read Dr. Schloss’s recent Senate testimony, go to <http://commerce.senate.gov/pdf/schloss-021506.pdf>  
To read about the Nanomedicine Roadmap Initiative, go to <http://nihroadmap.nih.gov/>